Highlights d Canonical NF-kB pathway is required for radiation-induced anti-tumor immunity 
In Brief
It is known that the NF-kB pathway plays a crucial role in supporting tumor initiation, progression, and the radioresistance of tumor cells. Hou et al. demonstrate that the deficiency of noncanonical NF-kB, but not canonical NF-kB, promotes radiation-induced antitumor immunity by regulating the STINGmediated type I IFN expression.
INTRODUCTION
Radiotherapy (RT) is widely used as a primary treatment modality for cancer, and the induction of damage to the tumor or to tumor stroma was long thought to be its major mode of action (Prise and O'Sullivan, 2009) . Recently, however, increasing evidence demonstrates that ionizing radiation (IR) induces tumor-specific immunity (Reits et al., 2006) and that anti-tumor immunity is required for the full anti-tumor effect of RT (Lee et al., 2009) . It is now recognized that the infiltration and priming of CD8 + T cells play a critical role in the efficacy of RT (Lee et al., 2009; Lugade et al., 2005; Takeshima et al., 2010) . DCs have been reported to be activated by local IR and required for CD8 + T cell activation and contribute to tumor control by RT (Gupta et al., 2012) . These antitumor immune responses have been found to be highly dependent on type I interferon (IFN) signaling (Burnette et al., 2011) . Type I IFNs promote dendritic cell (DC) function by stimulating their capacity to process and present antigens as well as to promote DC migration toward lymph nodes (Gardner and Ruffell, 2016; Zitvogel et al., 2015) . Stimulator of interferon genes (STING) is an endoplasmic-reticulum-associated protein that activates transcription of the type I IFN gene, via a STING-TBK kinase-IRF3 transcription factor-NF-kB signal transduction pathway (Weichselbaum et al., 2017) . Our previous studies demonstrated that STING-dependent cytosolic DNA sensing was required for IR-induced anti-tumor immunity by regulating type I IFN expression (Deng et al., 2014b) . However, emerging research also demonstrates that STING-induced IFN production by IR also promotes innate immune suppression by recruiting monocytic myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment . Thus, IR not only kills tumor cells directly, but also promotes innate immunity as well as adaptive immune responses via the STING-mediated DNA-sensing pathway. These immune responses induced by IR have important implications for control of localized cancers, as well as control of metastatic disease through the immunemediated abscopal effect. Therefore, elucidating the interaction of IR and the immune system may have a major impact on cancer treatment. The mammalian NF-kB family of transcription factors, including RelA, c-Rel, RelB, NF-kB1 (p50 and its precursor p105), and NF-kB2 (p52 and its precursor p100), play a central role in the immune system. The most well-studied activation pathway is the canonical NF-kB pathway, which mainly impinges upon RelA-p50 and c-Rel-p50 heterodimers (Hayden and Ghosh, 2008; Sun, 2012; Vallabhapurapu and Karin, 2009) . The activation of the non-canonical NF-kB pathway pivots on activation of RelB-p52 heterodimers in response to a subset of TNF family members, including CD40L, LTab, BAFF, RANKL, and TWEAK. In the presence of these ligands, cIAP1 and 2 degrades the TRAF3 ubiquitin ligase and NIK kinase stabilization is achieved. NIK then phosphorylates IKKa and IKKa phosphorylates p100, which is important for the subsequent ubiquitination and partial degradation of p100 by the proteasome to form p52. RelB-p52 heterodimers then translocate into the nucleus to regulate non-canonical NF-kB target genes (Sun, 2012) . and co-cultured with CD8 + T cells from naive 2C mice for 3 days and the cross-priming activity of BMDCs were analyzed by ELISPOT assays.
(legend continued on next page)
The canonical NF-kB signaling pathway has been extensively studied in the context of cancer initiation, progression, and response to RT and chemotherapy (chemo) in both mice and humans (Erstad and Cusack, 2013; Perkins, 2012; Shishodia and Aggarwal, 2004) . However, the involvement of the non-canonical NF-kB pathway in cancer biology, and in response to RT, is less well defined. Given that treatment with RT induces NF-kB activation in certain cancer cells and that the activation of NF-kB is associated with the development of radioresistance (Erstad and Cusack, 2013) , NF-kB pathways have been considered as a clinical target to counteract radio-and chemo-resistance. However, the role of the interaction of canonical and non-canonical NF-kB pathways in IR-induced anti-tumor immunity is largely unknown. An understanding the role and mechanism of NF-kB in RT may be of great value in designing therapeutic strategies that take advantage of host response in the context of RT.
In this study, we demonstrated that the canonical NF-kB pathway was required for IR-induced anti-tumor immune responses, suggesting that it is not a good therapeutic target to enhance the effect of IR. In contrast, the non-canonical NF-kB pathway negatively regulated RT-induced anti-tumor immunity through STING-dependent DC activation. We demonstrated that irradiated tumor cells activated the non-canonical NF-kB pathway in DCs in a STING-dependent manner and that the activated non-canonical NF-kB pathway controlled the antitumor functions of DCs and CD8 + T cells by regulating type I IFN expression. Importantly, inhibition of non-canonical NF-kB signaling with p52-RelB nuclear translocation blockade enhanced the therapeutic effect of RT. Thus, our findings demonstrate that the non-canonical NF-kB pathway inhibits IR-induced innate immune sensing and the resulting anti-tumor immunity. These findings provide a fresh direction for developing therapeutic strategies targeting NF-kB pathways.
RESULTS
Host Canonical NF-kB Signaling Is Required for IRInduced Anti-tumor Immunity To determine whether inhibition of the NF-kB pathway promotes the therapeutic effect of IR, we investigated tumor growth after IR in the presence of JSH-23, a canonical NF-kB pathway inhibitor. JSH-23 abrogated the anti-tumor effect of IR, which suggested that the canonical NF-kB pathway signaling was required for the therapeutic effect of IR ( Figures 1A and 1B) . Analysis of tumor-infiltrating immune cells profile revealed that the frequency of CD8 + T cells increased in irradiated tumors and decreased in the presence of JSH-23 ( Figure 1C ). Tumor-infiltrating DCs showed lower MHC-II and CD80 expression in JSH-23-treated mice than control mice ( Figures 1D and 1E ), which suggested that JSH-23 might alter the antigen-presenting capacity of DCs. Furthermore, our results here indicated that canonical NF-kB pathway inhibition dampened the cross-priming capacity of DCs after RT ( Figure 1F ). (Figures 2A and S1A) . A similar result was observed using a B16-SIY tumor model (Figures S1B and S1C), which suggested that the role of RelB in the anti-tumor effect of RT is not restricted to a specific tumor histology. In contrast, the tumor growth in Lyz2-cre Relb f/f mice was comparable with control mice following RT (Figures S1D and S1E), which suggested that RelB in DCs, but not myeloid cells (monocytes, mature macrophages, and granulocytes), plays an inhibitory role in IR-induced tumor control.
RelB is promiscuous in choosing binding partners depending on cell type and stimuli. Instead of its conventional partner, p52, it was reported that RelB could also promote DC activation as a RelB-p50 dimer regulated by the canonical NF-kB pathway (Shih et al., 2012) . To determine whether RelB in DCs controls the therapeutic effect of RT through the non-canonical NF-kB pathway, we employed NF-kB2-deficient (Nfkb2
À/À background. This genetic cross allowed us to focus on the role of NF-kB2 in DCs and rule out the effect of intrinsic defects after depletion of NF-kB2 in B cells (Caamañ o et al., 1998 Figure S2A ). NF-kB2-deficient DCs expressed higher MHC class I and II proteins and the co-stimulatory molecule CD80 ( Figure S2B ), which suggested more mature and higher cross-priming ability in Nfkb2 À/À mice. In an ELISPOT mice were used for co-culture with irradiated or nonirradiated MC38-SIY cells. Subsequently crosspriming activity of purified BMDCs was analyzed by ELISPOT assays as described in Figure 1F . À/À mice after IR ( Figure 3C ). We also found that the expression of CXCL10, a type I IFN-stimulated gene, was increased in Nfkb2 À/À mice after IR ( Figure 3D ). To further assess whether the non-canonical NF-kB pathway regulates IFN-b expression in DCs, we measured IFN-b production by BMDCs purified after co-culturing with control or irradiated tumor cells. The amount of secreted IFN-b protein was increased in NFkB2-deficient BMDCs stimulated with irradiated tumor cells (Figure 3E) . We also demonstrated that IFN-b production induced by irradiated tumor cells was increased in BMDCs derived from Itgaqx-cre Relb f/f mice compared to that from Relb f/f control mice ( Figure 3F ). Using type I IFN production as readout, we demonstrated that the non-canonical NF-kB pathway is a negative regulator of DC function following IR.
Non-canonical NF-kB Pathway Activation in DCs Is
Regulated by the STING-TBK1 Axis after IR The cGAS-STING pathway plays a critical role in anti-tumor immunity by regulating type I IFN expression (Woo et al., 2014) , and our previous studies indicate that STING drives IR-induced anti-tumor immunity by stimulating type I IFN expression (Deng et al., 2014b) . Therefore, we investigated whether the non-canonical NF-kB pathway controls STING-mediated type I IFN expression. To address this question, we utilized 5, 6 dimethylxanthenone-4-acetic acid (DMXAA), which is a direct ligand for murine STING and induces type I IFN expression in a STINGdependent manner (Corrales et al., 2015; Deng et al., 2014b) . While the production of IFN-b by BMDCs was increased by stimulation with DMXAA, IFN-b concentrations were even greater in NF-kB2-and RelB-deficient BMDCs compared with WT controls (Figures 3G and 3H ). These data suggested that the non-canonical NF-kB pathway is downstream of STING and therefore able to negate STING action in regulating IRinduced type I IFN expression.
Next, we investigated the activation of STING and non-canonical NF-kB pathways in BMDCs after co-culture with irradiated tumor cells. We found that irradiated tumor cells enhanced the phosphorylation of TBK1 and IRF3 and the activation of non-canonical NF-kB signaling in the BMDCs of WT mice ( Figures 4A,  4B , S3A, and S3B). Furthermore, we found that the enhanced activation of non-canonical NF-kB after co-culture with irradiated tumor cells was abolished in STING-deficient BMDCs ( Figures 4C and S3C ). These results suggested that STING activation is required for IR-induced activation of non-canonical NF-kB signaling in BMDCs. To determine whether STING activation is sufficient to activate non-canonical NF-kB, DMXAA was utilized to stimulate WT-and STING-deficient BMDCs. DMXAA treatment activated nuclear translocation of RelB in a STINGdependent manner ( Figures 4D and S3D ). As anticipated, TBK1 was also activated by DMXAA in a STING-dependent manner ( Figures 4D and S3D ). When TBK1 is deficient, DMXAA-induced activation of non-canonical NF-kB was abrogated ( Figures 4E and S3E ). These results suggested that TBK1 is a key regulator in STING-induced activation of the non-canonical NF-kB pathway.
To understand whether DNA from irradiated tumor cells is able to trigger the activation of non-canonical NF-kB signaling in DCs through the STING-mediated DNA-sensing pathway in tumor microenvironment, we labeled tumor DNA with EdU before inoculation and detected the up-take of tumor DNA and the activation of STING and non-canonical NF-kB pathways in DCs. As shown in Figure 4F , IR not only increased the up-take of tumor DNA in DCs in vivo, but also enhanced phosphorylation of TBK1 and p100 in WT DCs. In contrast, although DCs from STING-deficient mice showed comparable up-take of tumor DNA, the enhanced phosphorylation of TBK1 and p100 was abrogated. These data suggested that IR-induced up-take of tumor DNA in DCs subsequently activated TBK1 and non-canonical NF-kB signaling through the STING pathway.
To dissect which component in the non-canonical NF-kB pathway is the target of STING-TBK1, we examined the activation of up-stream components of the non-canonical NF-kB pathway in BMDCs after stimulation with DMXAA. The degradation of TRAF2 and 3, the accumulation of NIK, and the phosphorylation of IKKa were not altered by DMXAA (Figures 4G and S3F) . However, the phosphorylation of p100 (NF-kB2) was increased by DMXAA, suggesting that p100 could be the primary target of STING regulation. By using NF-kB2-deficient BMDCs, we found that p100-p52 was required for nuclear translocation of RelB during STING activation ( Figures 4H and S3G) . By using BMDCs derived from Chuk f/f (IKKa) or Itgax-cre Chuk f/f mice, our results revealed that activation of non-canonical NF-kB in IKKa-deficient BMDCs by DMXXA was comparable to that in WT cells ( Figures 4I and S3H ), suggesting that IKKa is dispensable in STING activation of RelB translocation. Furthermore, we observed direct binding between TBK1 and p100 in BMDCs stimulated with DMXAA by using co-IP assay (Figures 4J and S3I) . In vitro kinase assays showed that WT TBK1, but not TBK1 kinase loss-of-function mutants (including K38A dominant-negative mutation or kinase domain deletion), phosphorylated p100, which suggested that p100 is a substrate of TBK1 ( Figure 4K ). Taken together, these data suggest that irradiated tumor cells or a STING agonist can activate the STING pathway in DCs, which subsequently activates non-canonical NF-kB signaling in a TBK1-dependent manner. Figures 5G and S4G ), IFN-b production was abrogated. Inhibition of the canonical NF-kB pathway by JSH-23 also showed similar results ( Figures 5H and S4H ). These data suggest that both the TBK1-IRF3 and canonical NF-kB pathways are required for IR-induced Ifnb expression in DCs.
To understand how non-canonical NF-kB signaling negatively regulates type I IFN induction, we examined the effect of noncanonical NF-kB deficiency on STING-induced activation of signaling and transcriptional factors involved in Ifnb expression. The loss of NF-kB2 did not affect DMXAA-induced activation of either the TBK1-IRF3 or canonical NF-kB pathways, suggesting that the NF-kB2 pathway does not directly regulate the STING-TBK1-IRF3 axis ( Figures 5I and S4I ). Next we asked whether non-canonical NF-kB signaling suppressed type I IFN expression by inhibiting STING-induced transcriptional factors binding to the Ifnb promoter by Chromatin immunoprecipitation (ChIP) assays. The results showed that the binding of RelB to the Ifnb promoter was increased by DMXAA treatment in WT BMDCs, but not in NF-kB2-deficient cells ( Figure 5J) . Additionally, the binding of RelA to the Ifnb promoter was increased by DMXAA treatment in WT BMDCs, which was further elevated markedly in NF-kB2-deficient cells ( Figure 5K ). In contrast, the DMXAAinduced binding of IRF3 to the Ifnb promoter was comparable between WT and NF-kB2-deficient BMDCs ( Figure 5L ). These data suggest that non-canonical NF-kB signaling negatively regulates IR-induced type I IFN production by inhibiting binding of RelA to the Ifnb promoter without having an effect on the binding ability of IRF3.
To further explore the relationship between canonical and non-canonical NF-kB signaling in regulating the anti-tumor effect of IR, we monitored the tumor growth in Itgax-cre Relb f/f mice in the presence of JSH-23. The result showed that the enhanced anti-tumor effect in Itgax-cre Relb f/f mice was abrogated by JSH-23, which suggested that canonical NF-kB was required for an enhanced anti-tumor effect in RelB-deficient mice ( Figures  2A and S4J) . Furthermore, canonical NF-kB signaling in DCs contributed to the anti-tumor effect of IR by inducing IFN-b, since administration of exogenous IFN-b restored the anti-tumor effect of IR in Itgax-cre Rela f/f mice ( Figures 1G and S4K ).
Inhibition of Non-canonical NF-kB Signaling Can Promote IR-Induced Anti-tumor Immunity
To further investigate the role of non-canonical NF-kB signaling in the context of the clinical response of human cancer patients, we analyzed overall survival of patients receiving RT for glioblastoma (GBM) in a publicly available database (The Cancer Genome Atlas [TCGA]); we found that patients with low Nfkb2 expression had better overall survival after RT ( Figure S5A ). A (J) WT BMDCs were stimulated with 50 mg/mL DMXAA for indicated time in presence of 20 mM MG132. Whole-cell lysates were subjected to p100 or TBK1 followed by detecting p100 or TBK1 associated TBK1 or p100 by immuno-blotting.
(K) In vitro kinase assay of TBK1 WT, K38A (Lys38 mutated to Ala), and KDD (kinase domain depletion) on substrate p100. The rate of ADP production was detected to reflect the kinetics of the kinase reaction.
Representative data are shown from three experiments (one experiment for K). Data are represented as mean ± SD; ***p < 0.001. Please also see Figure S3 . similar result was obtained when the overall survival was analyzed based on the Relb expression ( Figure S5B ). These results suggest that non-canonical NF-kB signaling diminishes the therapeutic effect of IR not only in pre-clinical tumor models, but also in patient clinical response. We hypothesize that the inhibition of the non-canonical NF-kB pathway may be used as a translational strategy to enhance RT-induced anti-tumor effects. To address this question, we employed a competitive inhibitor (SN52) of NF-kB2 (Xu et al., 2008) , which inhibits the nuclear translocation of p52-RelB heterodimers. SN52, but not SN52Mu (a mutant control for SN52), inhibited DMXAA-induced nuclear translocation of RelB in BMDCs ( Figure S5C ). In contrast, treatment with SN52 did not change the activation of canonical NF-kB signaling. Furthermore, we found that nuclear translocation of RelB was increased in DCs isolated from irradiated tumors, and this activation was abolished by SN52 intratumoral (i.t.) treatment ( Figure S5D ). Consistent with the results of NF-kB2-deficient cells, inhibition of noncanonical NF-kB by SN52 increased Ifnb expression in BMDCs stimulated with irradiated tumor cells or STING agonist ( Figures  6A and S5E ). These results demonstrate that SN52 can effectively recapitulate the phenotype of non-canonical NF-kB deletion, resulting in alleviation of the negative regulation on IR-or STING-induced IFN-b production. To test the efficacy of SN52 in vivo, we administrated SN52Mu and SN52 i.t. immediately after IR. The combination of SN52 and IR enhanced anti-tumor immune functions of both DCs ( Figure 6B ) and CD8 + T cells (Figure 6C ) and subsequently reduced tumor burden ( Figures 6D and  S5F ) more effectively compared with IR alone, suggesting that non-canonical NF-kB inhibition can potentiate the anti-tumor effect of IR. We next tested whether the combination of IR and SN52 produced an abscopal effect by using a contralateral tumor model, in which the primary tumors were treated with IR and/or SN52 and the secondary tumors did not receive any treatment. A growth delay was observed in the IR+SN52 group but not in groups receiving either treatment alone ( Figure 6E ). These results suggested that non-canonical NF-kB inhibition also promoted systemic anti-tumor immunity induced by IR. To further test whether SN52 promoted the therapeutic effect of IR through the STING-IFNs axis, we investigated tumor growth in STINGdeficient mice ( Figure 6F ) and in the presence of IFNAR1-blocking antibody ( Figure 6G ) following treatment with IR and/or SN52. The results indicated that STING and type I IFNs were required for SN52-enhanced anti-tumor effects of RT.
Although SN52 promoted the therapeutic effect of IR by regulating type I IFNs, the tumors that received combination treatment were not completely eliminated. Sustained IFN-I signaling induces immunosuppressive mechanisms, including the expression of both PD-L1 on DCs and other myeloid cells and PD-1 on T cells, which result in CD8 + T cell exhaustion (Garcia-Diaz et al., 2017; Tang et al., 2018) . Therefore, we treated tumor-bearing mice with anti-PD-L1 after SN52 and IR treatment. PD-L1 blockade enhanced the therapeutic effect of the SN52+IR combination ( Figure 6H ) and led to tumor rejection ( Figure S5G ). To address whether this combination treatment resulted in generation of prolonged protective T cell immunity, tumor-free mice were rechallenged with higher dose of MC38 tumor cells on the opposite flank. No palpable tumors were detected on the treated mice after a few weeks ( Figure 6I ). Together, combining IR with manipulation of the STING-IFN pathway and checkpoint inhibition for better innate priming and alleviation of immunosuppression may present a fresh avenue for cancer therapy.
DISCUSSION
Radiation induces both innate and adaptive anti-tumor immune responses, and the axis of DCs and CTLs plays a crucial role in this process (Gupta et al., 2012; Lee et al., 2009) . Type I IFNs induced by IR are essential for both cross-presentation capacity of dendritic cells and anti-tumoral function of CD8 + T cells (Burnette et al., 2011; Zitvogel et al., 2015) . Our previous work established that the cGAS-and STING-dependent cytosolic DNA-sensing pathways in DCs are required for type I IFN induction after IR (Deng et al., 2014b) . In this report, we identify a previously unknown downstream control mechanism of the DNA-sensing pathway in DCs that has particular relevance to Representative data are shown from three experiments with 3-5 duplicated samples in each group. Data are represented as mean ± SD; **p < 0.01 and ***p < 0.001. Please also see Figure S4 . Figure 6 . Inhibition of Non-canonical NF-kB Can Promote Radiation-Induced Anti-tumor Immunity (A) WT BMDCs were pretreated with 40 mg/mL N52Mu or SN52 for 30 min and then co-cultured with irradiated or non-irradiated MC38 cells. ELISA assay was performed to measure IFN-b produced by purified BMDCs as described in Figure 3E .
(B and C) MC38-SIY tumors (B) and MC38 tumors (C) established in B6 mice were treated locally with one dose of 20 Gy IR. 40 mg SN52Mu or SN52 was administered i.t. in tumor-bearing mice on day À1, day 1, and day 3 of radiation.
(B) On day 4 post IR, tumors were removed and the cross-priming ability of DCs was evaluated by counting IFN-g + spots as described in Figure 2C .
(C) On day 7 post IR, TDLNs were removed and tumor antigen-specific CD8 + T cell function was measured by ELISPOT assays as described in Figure 2F .
(D) MC38 tumors established in B6 mice were treated with one dose of 20 Gy IR. 40 mg SN52Mu or SN52 was administered i.t. every 2 days for a total of four times staring from 1 day before radiation. Tumor growth was monitored after radiation.
(legend continued on next page) cancer therapy. Our data demonstrate that the innate DNAsensing pathway not only exerts immunostimulatory functions via IFN production, but also activates the non-canonical NF-kB pathway, which in turn negatively regulates type I IFN induction after IR. These results describe an alternative mechanism of STING regulation and indicates that targeting the non-canonical NF-kB pathway enhanced anti-tumor effects of IR. We found that irradiated tumor cells stimulated the activation of the non-canonical NF-kB pathway in DCs in a STING-TBK1-dependent manner. Activation of the STING pathway was both necessary and sufficient for the activation of the non-canonical NF-kB pathway. The stabilization of NIK and phosphorylation of IKKa are well known as central early steps in activation of non-canonical NF-kB pathway (Vallabhapurapu and Karin, 2009) . Jin et al. (2012) found that TBK1 controls IgA class switching in B cells by negatively regulating phosphorylation and subsequent degradation of NIK. Cytosolic DNA can activate the non-canonical NF-kB pathway in a STING-dependent and TBK1-independent manner in MEFs or human tumor cells (Abe and Barber, 2014; Bakhoum et al., 2018) . However, our data demonstrated that DMXAA, a STING agonist, did not increase the accumulation of NIK or phosphorylation of IKKa in the process of activating p100 phosphorylation and nuclear translocation of p52-RelB heterodimers. Rather, our results suggest that in response to IR-induced damage, host immune cells may preferentially use the cGAS-STING DNA-sensing pathway, instead of NIK-IKKa, to activate the non-canonical NF-kB pathway. Understanding this alternative regulation would be of value for choosing or designing inhibitors of the non-canonical NF-kB pathway to enhance the therapeutic effect of IR as well as therapies in virus infection and auto-immune diseases. It is intriguing that activation of the STING pathway induced both the canonical (triggering production of IFN) and the non-canonical (inhibiting IFN production) NF-kB pathways in DCs. This may represent an intricate and complex regulation of IFN production responding to differential stimuli.
A growing body of evidence shows that the canonical NF-kB pathway plays a crucial role in supporting tumor initiation and progression via mechanisms including stimulating cell proliferation, inhibiting apoptosis (Beg and Baltimore, 1996) , increasing metastasis (Wang et al., 1999) , and angiogenesis (Koch et al., 1992) . Radiation induces constitutive canonical NF-kB activation in certain cancers (Brach et al., 1991; Chen et al., 2002) , and activation of NF-kB is associated with the development of radioresistance. Given this evidence, a large number of inhibitors of canonical NF-kB pathway are undergoing development and some have been tested in clinical trials. However, the anti-tumor efficacy and toxicity of these inhibitors are not promising. In our present study, an inhibitor of the canonical NF-kB pathway decreased the therapeutic effect of IR by suppressing IRinduced anti-tumor immune response. Specifically, canonical NF-kB, together with IRF3, is required for the induction of type I IFN in DCs stimulated by irradiated tumor cells through STING-TBK1 signaling. Taken together, the canonical NF-kB pathway may not be an ideal target for promoting the therapeutic effect of IR because of its differential roles in inducing tumor radioresistance and its requirement for IR-induced anti-tumor immunity. Similar to the canonical NF-kB pathway, non-canonical NF-kB is also known as a tumor-promoting factor due to its role in regulating the expression of BIM, BMF (Vallabhapurapu et al., 2015) , and BCL2 (Wang et al., 2007) in tumor cells. In addition, non-canonical NF-kB signaling in tumor cells is reported to be activated by IR and mediates radioresistance by regulating the expression of MnSOD (Josson et al., 2006) , Survivin, and BCL2 (Mineva et al., 2009 ). However, we found that, in contrast to canonical NF-kB, the non-canonical NF-kB pathway in DCs negatively regulates IR-induced anti-tumor immunity by controlling type I IFN expression. Consistently, we found that noncanonical NF-kB inhibition, but not canonical NF-kB inhibition, promoted tumor regression induced by local IR. We have previously shown that, in some tumors, intrinsic radiobiological properties of the tumor cells are less important than the immune microenvironments (Liang et al., 2013) and, in this context, inhibiting the non-canonical NF-kB pathway may be particularly important. Our findings reveal a molecular mechanism of IRmediated anti-tumor immunity through an alternative model of STING regulation and provide insight into therapeutic strategies targeting the NF-kB pathway in cancer immunotherapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: every 2 days for a total of four times staring from 1 day before radiation. Tumor growth was monitored after radiation. (G) MC38 tumors established in B6 mice were treated with one dose of 20 Gy IR. 40 mg SN52Mu or SN52 was administered i.t. every 2 days for a total of four times staring from 1 day before radiation. All mice were treated with 200 mg anti-IFNAR1 as described in Figure 3A . Tumor growth was monitored after radiation.
(H) MC38 tumors in B6 mice were established and treated with IR and SN52 as described in (D). On the day of IR, 200 mg anti-PD-L1 (10F.9G2) or isotype control were given by i.p. every 3 days for a total of four times. Tumor growth was monitored after IR. (I) Thirty days after tumor eradication, tumor-free mice from anti-PD-L1+SN52+IR treatment group were rechallenged with 2 3 10 6 MC38 cells on the opposite flank. Tumor growth on naive and tumor-free mice was monitored.
Representative data are shown from three experiments (one experiment for F and G) conducted with 4-6 mice in each group. Data are represented as mean ± SD; *p < 0.05, **p < 0.01, and ***p < 0.001. Please also see Figure S5 . 
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